Ipilimumab Biosimilar - Research Grade

Human

CTLA-4

>1mg/ml

Human IgG1 Kappa

Humanized

Anti-CTLA-4 (9H10) In Vivo Antibody - Low Endotoxin (ICH1084), Anti-Mouse CTLA-4 (UC10-4F10-11) In Vivo Antibody - Low Endotoxin (ICH1085), Anti-Mouse CTLA-4 (9D9) In Vivo Antibody - Low Endotoxin (ICH1096), Tremelimumab Biosimilar - Research Grade (ICH5184), Botensilimab Biosimilar - Research Grade (ICH5412), Evalstotug Biosimilar - Research Grade (ICH5538), Firastotug Biosimilar - Research Grade (ICH5550), Gotistobart Biosimilar - Research Grade (ICH5583), Muzastotug Biosimilar - Research Grade (ICH5696), Nurulimab Biosimilar - Research Grade (ICH5717), Quavonlimab Biosimilar - Research Grade (ICH5794), Sovipostobart Biosimilar - Research Grade (ICH5879), Tazlestobart Biosimilar - Research Grade (ICH5904), Tuvonralimab Biosimilar - Research Grade (ICH5951), Vilastobart Biosimilar - Research Grade (ICH5979), Zalifrelimab Biosimilar - Research Grade (ICH5998)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P16410

1493

RRID:AB_2921540

Blue ice

This is a research-grade, unconjugated recombinant analog of ipilimumab, a fully human IgG1 kappa antibody directed against human CTLA-4. It is supplied for research use only as a non-therapeutic reagent and is not the clinical drug; it is not intended for human or veterinary use. Because it reproduces the antigen-binding specificity of the originator against CTLA-4, it is useful as a defined, lot-consistent tool for in-vitro and preclinical studies of checkpoint biology: as a positive binding/blocking control, a benchmarking reference in competitive assays, a capture or detection reagent, and a starting scaffold for ADCC, ADC, or engineering workflows. The human IgG1 backbone supports Fc-dependent readouts such as ADCC and complement engagement where relevant. Material is offered at research-grade low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities, making it suitable for assay development, screening, and scale-dependent functional work where reproducible checkpoint-blocking reference material is needed. CTLA-4 (CD152) is an inhibitory immune checkpoint receptor expressed on activated conventional T cells and constitutively on regulatory T cells (Tregs). It shares the ligands CD80 (B7-1) and CD86 (B7-2) with the co-stimulatory receptor CD28 but binds them with substantially higher affinity, outcompeting CD28 and dampening T-cell activation. CTLA-4 acts largely during the priming phase in secondary lymphoid tissue, raising the threshold for activation and contributing to peripheral tolerance; it can also physically remove B7 ligands from antigen-presenting cells by trans-endocytosis. On Tregs, CTLA-4 is central to their suppressive function. Antibody blockade of CTLA-4 releases this inhibition and can enhance effector T-cell responses and, via Fc-mediated mechanisms, deplete intratumoral Tregs, which underlies its interest in antitumor immunity research. Encoded by CTLA4; UniProt P16410.

Ctla4, Cytotoxic T-lymphocyte protein 4, CD152

Detects human CTLA-4. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ipilimumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0004

Ipilimumab (anti-CTLA-4) Biosimilar

Q: Is the Ipilimumab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Ipilimumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ipilimumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Ipilimumab that binds human CTLA-4; for research use only (RUO).